Inactive Instrument

INSYS Therapeutics, Inc.

Equities

Insys Therapeutics Announces Earnings Guidance for the First Quarter of 2016

April 11, 2016 at 07:22 am EDT

Insys Therapeutics Announced earnings guidance for the first quarter of 2016. The company reported preliminary estimated revenues from Subsys (fentanyl sublingual spray) for first quarter of 2016, which reflects a decline in demand. The company expects first quarter will be in the range of $61 million to $62 million.

Estimated revenues for the quarter reflect a decline in demand, as Subsys prescription volumes were down, as well as a reduction in wholesale inventory levels. The company estimates the decrease in wholesale channel inventory levels to be in the range of $7 million.

Latest news about INSYS Therapeutics, Inc.

INSYS Therapeutics, Inc.'s Equity Buyback announced on November 5, 2015, has expired.	20-03-30	CI
INSYS Therapeutics, Inc. Went Out of Business	20-02-17	CI
Bankruptcy Judge Changed for INSYS Therapeutics, Inc.	20-02-05	CI
Second Motion for Exclusivity Period Extension Approved For INSYS Therapeutics, Inc.	20-01-21	CI
Modified Second Amended Liquidation Plan Approved for INSYS Therapeutics, Inc.	20-01-16	CI
Renaissance Lakewood, LLC completed the acquisition of certain assets of INSYS Therapeutics, Inc. (OTCPK:INSY.Q).	19-12-18	CI
Motion for Asset Sale Approved for INSYS Therapeutics, Inc.	19-12-16	CI
Second Amended Disclosure Statement Approved for INSYS Therapeutics, Inc.	19-12-04	CI
Renaissance Lakewood, LLC entered into an asset purchase agreement to acquire certain assets of INSYS Therapeutics, Inc. (OTCPK:INSY.Q) for $0.28 million.	19-12-02	CI
Second Amended Liquidation Plan And Disclosure Statement Filed by INSYS Therapeutics, Inc.	19-11-29	CI
First Amended Liquidation Plan Filed by INSYS Therapeutics, Inc.	19-11-14	CI
First Motion for Exclusivity Period Extension Approved For INSYS Therapeutics, Inc.	19-11-04	CI
Chilion Group Holdings US, Inc. completed the acquisition of Assets from INSYS Therapeutics, Inc. (OTCPK:INSY.Q) for $12.3 million.	19-10-30	CI
INSYS Therapeutics, Inc. Announces Resignation of Andrew G. Long, Chief Executive Officer, Board of Directors, Effective November 8, 2019	19-10-25	CI
Motion for Asset Sale Approved for INSYS Therapeutics, Inc.	19-10-16	CI
First Motion for Exclusivity Period Extension Filed by INSYS Therapeutics, Inc.	19-10-07	CI
Motion for Case Conversion Filed for INSYS Therapeutics, Inc.	19-09-25	CI
Pharmbio Korea Co., Ltd. agreed to acquire certain assets of Insys Therapeutics, Inc.	19-09-24	CI
Insys Therapeutics : Drugmaker Insys wins bankruptcy court approval to sell off opioid	19-09-19	RE
Motion for Asset Sale Approved for INSYS Therapeutics, Inc.	19-09-19	CI
Joint Liquidation Plan and Disclosure Statement Filed by INSYS Therapeutics, Inc.	19-09-17	CI
BTcP Pharma, LLC entered into an asset purchase agreement to acquire Fentanyl sublingual spray product from INSYS Therapeutics, Inc.	19-09-02	CI
Hikma Pharmaceuticals USA Inc. completed the acquisition of Naloxone And Epinephrine Nasal Sprays from INSYS Therapeutics, Inc. (OTCPK:INSY.Q).	19-08-28	CI
Motion for Asset Sale Approved for INSYS Therapeutics, Inc.	19-08-23	CI
Motion for Asset Sale Approved for INSYS Therapeutics, Inc.	19-08-22	CI

Chart INSYS Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company's lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.

Sector

More about the company